Sheng‐chieh Hsu - Gynecology

Author Information

Dr. Sheng-chieh Hsu is associated with the Graduate Institute of Biomedical Sciences, College of Medicine at Chang Gung University in Tao-Yuan, Taiwan. Additionally, Dr. Hsu is affiliated with the Department of Biomedical Sciences at the same institution and serves at the Department of Obstetrics and Gynecology at Chang Gung Memorial Hospital, Linkou, Taiwan. The affiliation details were sourced from PubMed.

Research Contributions

Dr. Sheng-chieh Hsu has made significant contributions to the field of cancer biology, particularly in understanding the metabolic and epigenetic mechanisms involved in cancer progression and therapy. His research has extensively explored the role of arginine metabolism, epigenetic regulation, and the cGAS-STING pathway in cancer. Notable works include studies on arginine starvation and its impact on chromatin leakage, as well as the modulation of oxidative phosphorylation (OXPHOS) in prostate cancer cells. Dr. Hsu's research also delves into the genetic mutations affecting cancer cell metabolism and the development of small molecule inhibitors to resensitize multidrug-resistant cancer cells to conventional therapies.

Aliases

Dr. Sheng-chieh Hsu is also known by several aliases, including S C Hsu, Sheng-chie Hsu, and Sheng‒chieh Hsu.

Publication and Citation Metrics

Metric	Value
Citation Count	3181
h-index	24
Paper Count	53

Publications:

Arginine starvation elicits chromatin leakage and cGAS-STING activation via epigenetic silencing of metabolic and DNA-repair genes

DOI: 10.7150/thno.54695

Year: 2021

Arginine is an epigenetic regulator targeting TEAD4 to modulate OXPHOS in prostate cancer cells

DOI: 10.1038/s41467-021-22652-9

Year: 2021

Arginine Signaling and Cancer Metabolism

DOI: 10.3390/cancers13143541

Year: 2021

Mutations in the PKM2 exon-10 region are associated with reduced allostery and increased nuclear translocation

DOI: 10.1038/s42003-019-0343-4

Year: 2019

Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors

DOI: 10.1016/B978-0-12-816435-8.00011-0

Year: 2019

The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

DOI: 10.1016/j.canlet.2019.01.001

Year: 2019

Mutations in the PKM2 exon-10 region are associated with reduced allostery and increased nuclear translocation.

DOI: 10.1038/s42003-019-0343-4

Year: 2019

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC

DOI: 10.1038/s41388-018-0414-x

Year: 2018

Abstract 3502: RNAi screen identified novel long non-coding RNAs involved in cell growth control, migration, and invasion

DOI: 10.1158/1538-7445.AM2017-3502

Year: 2017

Abstract B48: Epigenetic reprogramming of mitochondrial and metabolic functions plays a key role in arginine-deprivation based cancer therapy

DOI: 10.1158/1538-7445.CHROMEPI15-B48

Year: 2016

Can Menstrual Sponges Cause Toxic Shock Syndrome (TSS)?

How are Cultures and Swabs Collected?

Why is Site Care Important?

Why Measure Serum Progesterone Levels?

How do Milk Ducts Function?

What is TOLAC?

What are the Complications of Untreated Syphilis?

What Is the Impact of Good Peer Review in Gynecology?

How Can Women Advocate for Their Health?

When is an Elective Cesarean Section Considered?

Partnered Content Networks

Relevant Topics